We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Apolipoprotein B Singled Out as Heart Attack Risk Predictor

By LabMedica International staff writers
Posted on 09 Dec 2021
The selection of risk factors is based on what makes a highly significant independent contribution to predicting risk. More...
Age, sex, smoking, systolic blood pressure and total cholesterol are well known to be important. Also, diabetes and left ventricular hypertrophy increase risk as does a previous stroke or heart attack.

Apolipoprotein B (Apo B) is a major protein component of low-density lipoprotein (LDL) comprising >90% of the LDL proteins and constituting 20-25% of the total weight of LDL. Apo B exists in two forms. Apo B-100, the most abundant form of Apo B, is found in lipoproteins synthesized by the liver including LDL, VLDL, and IDL. Lipid management typically focuses on levels of low-density lipoprotein cholesterol (LDL-C) and, to a lesser extent, triglycerides (TG).

Cardiologists at the Brigham and Women’s Hospital (Boston, MA, USA) and their colleagues carried out prospective cohort analysis included individuals from the population-based UK Biobank and from two large international clinical trials. The median (IQR) follow-up was 11.1 (10.4-11.8) years in UK Biobank and 2.5 (2.0-4.7) years in the clinical trials.

Two populations were studied in this analysis: 389,529 individuals in the primary prevention group who were not taking lipid-lowering therapy and 40,430 patients with established atherosclerosis who were receiving statin treatment. Of the 389,529 individuals in the primary prevention group, 224,097 (58%) were female, and the median (IQR) age was 56.0 (49.5-62.5) years. Of the 40,430 patients with established atherosclerosis, 9647 (24%) were female, and the median (IQR) age was 63 (56.2-69.0) years. The scientist determined whether common measures of cholesterol concentration, TG concentration, or their ratio are associated with cardiovascular risk beyond the number of apolipoprotein B (apoB)–containing lipoproteins.

The investigators reported that in the primary prevention cohort, apoB, non–HDL-C, and TG each individually were associated with incident myocardial infarction (MI). However, when assessed together, only apoB was associated (adjusted hazard ratio [aHR] per 1 SD, 1.27; P < .001). Similarly, only apoB was associated with MI in the secondary prevention cohort. Adjusting for apoB, there was no association between the ratio of TG to LDL-C (a surrogate for the ratio of TG-rich lipoproteins to LDL) and risk of MI, implying that for a given concentration of apoB-containing lipoproteins, the relative proportions of particle subpopulations may no longer be a predictor of risk.

Nicholas Marston, MD, MPH, a Cardiologist and lead author of the study said, “We looked at apolipoprotein B, non-HDL cholesterol, and triglycerides, and all three are predictive of risk when you look at them independently and without adjustment. Even when you adjust for clinical factors, each were predictive of MI, which is the endpoint of interest in this study. However, when you also adjusted for the other lipid parameters, apolipoprotein B was the only one that remained significant.”

The authors concluded that in the cohort study, risk of MI was best captured by the number of apoB-containing lipoproteins, independent from lipid content (cholesterol or TG) or type of lipoprotein (LDL or TG-rich). This suggests that apoB may be the primary driver of atherosclerosis and that lowering the concentration of all apoB-containing lipoproteins should be the focus of therapeutic strategies. The study was published on November 13, 2021 in the journal JAMA Cardiology.

Related Links:
Brigham and Women’s Hospital


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.